#United States #Los Angeles #Securities Fraud #Soleno Therapeutics #DCCR Drug

An Opportunity for Soleno Therapeutics Investors

The Law Offices of Frank R. Cruz recently made an announcement highlighting an important opportunity for investors who have experienced losses in their shares of Soleno Therapeutics, Inc. (NASDAQ: SLNO). This comes in light of allegations surrounding significant misrepresentation and concealment of safety issues pertaining to their flagship product, DCCR, during clinical trials.

Understanding the Allegations

The class action lawsuit revolves around claims that from March 26, 2025, to November 4, 2026, Soleno executives allegedly failed to inform investors about critical safety concerns related to the Phase 3 clinical trial of DCCR. The issues allegedly included complications like excessive fluid retention among participants, which the company is accused of downplaying. The consequences of these incomplete disclosures led investors to believe that DCCR was a viable treatment for hyperphagia in patients with Prader-Willi syndrome (PWS), ultimately misrepresenting its safety profile and commercial viability.

Key Issues Raised

1. Concealed Safety Risks: During the clinical trials, significant evidence regarding the risks associated with DCCR was allegedly misrepresented or concealed, which might have influenced investor decisions.
2. Impact on Commercial Viability: The lawsuit suggests that the actual risks involved, including adverse effects that may arise after the drug's commercial launch, were not disclosed adequately. This includes concerns such as higher patient dropout rates, reluctance from prescribers, and possible repercussions on Soleno's market standing.
3. Misleading Statements from Executives: The lawsuit contends that public statements made by Soleno regarding its business health and prospects were not just optimistic but materially misleading, impacting stock valuations unjustly as a result.

Important Dates and Actions

Investors who incurred losses are encouraged to consider their participation in the ongoing class action lawsuit. The deadline for becoming a lead plaintiff is set for May 5, 2026. Interested parties should act before this date to ensure they can have a say in the proceedings.

How to Participate

For those wishing to learn more or to express interest in joining the lawsuit, there are options available:

• - Contact the Law Offices of Frank R. Cruz: Interested individuals should reach out via email or phone. Providing personal details like mailing address and the number of shares purchased will help facilitate the legal process.
• - Stay Informed: Potential plaintiffs are also advised to follow updates from the legal team regarding progress, timelines, and any necessary actions required from shareholders.
• - Retain or Seek Legal Counsel: Investors have the option to seek legal representation of their choice or can opt to remain as absent members of the class while still being eligible for any potential settlements.

Conclusion

This unfolding situation provides a significant opportunity for investors of Soleno Therapeutics who may feel that their investment decisions were compromised by lack of crucial safety disclosures. Engaging with legal counsel and participating in the class action could potentially lead to recovery of some losses experienced as a result of the alleged misconduct by the company.

The ripple effects from this case underscore the importance of transparency in clinical testing and the responsibilities companies hold towards their investors. As this lawsuit progresses, it will be a focal point for many concerned shareholders looking for justice and accountability within the pharmaceutical industry.

For more information on this legal matter, feel free to visit www.frankcruzlaw.com and follow the updates on their Twitter handle @FRC_LAW. Investors are advised to act quickly in order to secure their place in this significant legal action.